Clasp Therapeutics aims to bring absolute precision to immuno-oncology by developing next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations across hard-to-treat cancers
Clasp Therapeutics aims to bring absolute precision to immuno-oncology by developing next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations across hard-to-treat cancers. Clasp is developing T cell engagers to match both the specific characteristics of the patient’s immune system and the specific genetics of their tumor, enabling the creation of exquisitely personalized, yet off-the-shelf, therapeutics.